Jan. 3 Financial Quick Takes: Black Diamond plots IPO; plus Oxford Nanopore, CF PharmTech, Mygene and Zerun

Black Diamond seeking NASDAQ listing
Tumor-agnostic precision oncology company Black Diamond Therapeutics Inc. filed for an IPO on NASDAQ worth up to $100 million. Shepherded since 2017 by lead investor Versant Ventures, the company is building a pipeline based on its Mutation-Allostery-Pharmacology (MAP) platform; lead candidate BDTX-189, which targets EGFR and HER2 mutations, is due to begin a Phase I/II trial this year. Versant holds a 42.1% stake in Black Diamond, while New Enterprise Associates holds 11.2%, RA Capital 6.7% and Boxer Capital 5.6% (see "$85M Series C").

Oxford Nanopore raises £29.3M
Sequencing company Oxford Nanopore Technologies Ltd. raised £29.3 million ($38.4 million) in equity capital and facilitated an £80.2 million secondary offering for existing shareholders. New and existing investors from the U.S., Europe and the Asia/Pacific region participated. IP Group plc (LSE:IPO) said it realized £22 million from a partial sale of its stake, which stands at 16.4% following the transactions' completion. The Edinburgh Worldwide Investment Trust plc affiliate of Baillie Gifford acknowledged in a Dec. 17 financial report that it had obtained shares that had become available recently. Oxford Nanopore declined to comment on whether funds formerly managed by Woodford Investment Management were among the selling shareholders. That firm had previously invested in Oxford Nanopore; following Woodford's removal, the funds' managers are seeking buyers for its holdings (see "Empire Crumbles")...